About LYRIC BIO

Lyric Bio is developing high-density tissue-mimicking bioreactors that utilize a proprietary laser-printed cellular substrate to produce human immunoglobulin Ig from a single donor, significantly reducing the reliance on multiple plasma donations. This technology addresses the critical shortage of Ig therapies by enabling scalable and cost-effective production, improving access to life-saving treatments for patients with various diseases.

```xml <problem> Current methods of producing human immunoglobulin (Ig) therapies rely on large volumes of plasma donations, requiring an average of 10 plasma donations to produce a single dose of intravenous immunoglobulin (IVIg). This dependence on plasma donors results in high production costs, supply chain instability, and limited access to life-saving therapies. Standard biomanufacturing processes are unable to produce complex therapeutics at scale, exacerbating the global shortage of critical Ig therapies. </problem> <solution> Lyric Bio is developing high-density, tissue-mimicking bioreactors that leverage a proprietary laser-printed cellular substrate to enable the scalable manufacturing of human Ig from a single donor. This technology significantly reduces the reliance on multiple plasma donations, potentially producing 1,000 or more doses from a single donor. By replicating biological tissue within a palm-sized bioreactor, Lyric Bio's approach facilitates ultra-high-density cell growth and continuous production of human immunoglobulin. This innovative biomanufacturing process aims to improve product consistency, enhance quality control, and alleviate donor dependency, ultimately expanding access to life-saving Ig therapies for patients with various diseases. </solution> <features> - Proprietary laser-printed cellular substrate that supports ultra-high-density cell growth - Tissue-mimicking bioreactors that replicate biological tissue for Ig production - Scalable manufacturing process that reduces reliance on human plasma donations by several orders of magnitude - Continuous production of human immunoglobulin from a single donor - Improved product consistency and quality control through advanced manufacturing processes </features> <target_audience> The primary target audience includes pharmaceutical companies and healthcare providers seeking to improve the accessibility, affordability, and supply chain stability of human immunoglobulin (Ig) therapies. </target_audience> ```

What does LYRIC BIO do?

Where is LYRIC BIO located?

LYRIC BIO is based in Ville d'Anaunia, Italia.

When was LYRIC BIO founded?

LYRIC BIO was founded in 2024.

Location

Ville d'Anaunia, Italia

Founded

2024

Employees

2 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

LYRIC BIO

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

lyricbio.com 100+

Founded 2024 – Ville d'Anaunia, Italia

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Current methods of producing human immunoglobulin (Ig) therapies rely on large volumes of plasma donations, requiring an average of 10 plasma donations to produce a single dose of intravenous immunoglobulin (IVIg). This dependence on plasma donors results in high production costs, supply chain instability, and limited access to life-saving therapies. Standard biomanufacturing processes are unable to produce complex therapeutics at scale, exacerbating the global shortage of critical Ig therapies.

Solution

Lyric Bio is developing high-density, tissue-mimicking bioreactors that leverage a proprietary laser-printed cellular substrate to enable the scalable manufacturing of human Ig from a single donor. This technology significantly reduces the reliance on multiple plasma donations, potentially producing 1,000 or more doses from a single donor. By replicating biological tissue within a palm-sized bioreactor, Lyric Bio's approach facilitates ultra-high-density cell growth and continuous production of human immunoglobulin. This innovative biomanufacturing process aims to improve product consistency, enhance quality control, and alleviate donor dependency, ultimately expanding access to life-saving Ig therapies for patients with various diseases.

Features

Proprietary laser-printed cellular substrate that supports ultra-high-density cell growth

Tissue-mimicking bioreactors that replicate biological tissue for Ig production

Scalable manufacturing process that reduces reliance on human plasma donations by several orders of magnitude

Continuous production of human immunoglobulin from a single donor

Improved product consistency and quality control through advanced manufacturing processes

Target Audience

The primary target audience includes pharmaceutical companies and healthcare providers seeking to improve the accessibility, affordability, and supply chain stability of human immunoglobulin (Ig) therapies.